Followers | 275 |
Posts | 56221 |
Boards Moderated | 23 |
Alias Born | 08/29/2007 |
Sunday, May 05, 2024 12:33:45 PM
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent ABOS News
- Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference • GlobeNewswire Inc. • 10/31/2024 12:05:25 PM
- Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference • GlobeNewswire Inc. • 10/23/2024 12:00:00 PM
- Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference • GlobeNewswire Inc. • 09/30/2024 08:00:00 PM
- Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease • GlobeNewswire Inc. • 09/26/2024 12:00:00 PM
- Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024 • GlobeNewswire Inc. • 09/25/2024 08:00:00 PM
- Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference • GlobeNewswire Inc. • 09/03/2024 08:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:42:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 11:48:08 AM
- Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights • GlobeNewswire Inc. • 08/13/2024 11:00:00 AM
- Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024 • GlobeNewswire Inc. • 08/06/2024 08:00:00 PM
- Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease • GlobeNewswire Inc. • 07/29/2024 11:00:00 AM
- Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024 • GlobeNewswire Inc. • 07/28/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:54:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:51:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:49:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:46:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:41:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:36:13 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:47:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 11:35:38 AM
- Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights • GlobeNewswire Inc. • 05/14/2024 11:00:00 AM
- Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/13/2024 08:00:00 PM
- Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference • GlobeNewswire Inc. • 05/08/2024 09:47:25 PM
- Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease • GlobeNewswire Inc. • 05/08/2024 12:00:00 PM
- Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 08:00:00 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM